Hemab Therapeutics Holdings, Inc. (COAG)
Health Care · Biotechnology · NASDAQ
Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for rare blood coagulation disorders.
What Hemab Therapeutics Holdings, Inc. does
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. The company's pipeline consists of bispecific and monovalent antibodies targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease, as well as preclinical programs for heavy menstrual bleeding.
Themes: blood coagulation disorders, rare disease therapeutics, monoclonal antibodies, clinical-stage biopharma, hematology
Fundamentals
- Price$34.17 as of 2026-10-20 close
- Market cap$1.6B as of 2026-07-31 (share count; price 2026-10-20)
- P/En/a earnings data not available
- ROICn/a No figure: its 10-K tags no operating income.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta-0.92 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
Quarterly results
Balance sheet at 2026-06-30
- Cash and equivalents$237M
- Short-term investments$220M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Hemab Therapeutics Holdings, Inc. looks technically
Hemab Therapeutics Holdings, Inc. (COAG): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $40.32 | $40.32 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 27.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($27.38 to $34.53) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 95.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $55.42 (set on 2026-08-14) | $55.42 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $23.00 (set on 2026-05-11) | $23.00 |
| Above the all-time low | it is 48.6% above its all-time low | +48.6% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 31st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.73 between its high and its low — about 8.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $27.40 and $36.11 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $27.40 – $31.75 – $36.11 |
| Typical daily range (% of price) | its price moves about 8.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.0% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-09-04 has been "filled" 31 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 31 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +13.63% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.0 percentage points (the stock lost 17.0% while the market gained 1.0%) | -18.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 34.4 percentage points (the stock lost 30.8% while the market gained 3.6%) | -34.5% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 6 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 2 of 6 |
|---|---|---|
| Bearish technical signals | 2 of the 6 technical signals we can compute for it are currently in a bearish state: near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.4% of the share price. | -19.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid since 2026-05-01, so the typical buyer over that stretch is under water. That average is $38.05 — a volume-weighted average of daily closes over 109 sessions, not a true tick-by-tick VWAP. | -10.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $39.50 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -13.5% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 50-day moving average · in a strong, established uptrend (ADX) · Most volatile (6%+ typical daily range) · At the top of its 14-day range (stochastic above 80) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$61.20 range $58.00 – $65.00; median $60.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for COAG
- Consensus EPS estimate-$0.51 next reporting period, as of 2026-10-15
- Estimate change, 30 days$0.00 from -$0.51, on 2026-09-10, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no approved products and has never generated revenue, with a history of significant operating losses.","Substantial future capital requirements for late-stage clinical trials and potential commercialization infrastructure.","Clinical development is inherently uncertain, with the risk that product candidates fail to demonstrate safety or efficacy."]
What changed in the latest 10-Q
AI-assisted comparison of COAG's 10-Q filed 2026-08-11 against the prior one filed 2026-05-21.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds 'heavy menstrual bleeding' to the list of serious bleeding and thrombotic diseases in the second sentence of the Overview.
- Newer filing adds description of HMB-003 as 'an anti-fibrinolytic targeting plasmin inhibition in preclinical development to reduce bleeding across multiple high-unmet-need conditions, beginning with heavy menstrual bleeding'.
- Newer filing changes the cumulative gross proceeds period from 'Since our inception through May 21, 2026' to 'Since our inception through June 30, 2026'.
- Newer filing changes net loss figures from three months ended March 31, 2026/2025 ($22.7 million and $15.3 million) to six months ended June 30, 2026/2025 ($46.8 million and $27.5 million).
- Newer filing changes accumulated deficit from $204.5 million as of March 31, 2026 to $228.7 million as of June 30, 2026.
- Newer filing adds 'HMB-003 and' to the first bullet point under 'We anticipate that our expenses will increase substantially'.
- Newer filing adds 'to Gubra A/S, or Gubra, under our collaboration agreement with Gubra, or the Gubra Agreement,' to the milestone/royalty payments bullet point.
- Newer filing gives HMB-002's development a 'subcutaneous prophylactic treatment' description instead of just 'subcutaneous'.
- Newer filing adds a third bullet under 'In addition, our expenses will further increase if' about third-party challenges to intellectual property that is visible in the older filing but positioned in what appears to be the newer filing's continuation.
- Removed:
- Older filing's Overview did not include 'heavy menstrual bleeding' in the disease list.
- Older filing did not describe HMB-003 in the Overview.
- Reworded:
- Older filing: 'Since our inception through May 21, 2026, we have received aggregate gross proceeds of approximately $692.7 million' changed to 'Since our inception through June 30, 2026, we have received aggregate gross proceeds of approximately $692.7 million'.
- Older filing: 'Our net losses were $22.7 million and $15.3 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $204.5 million.' changed to 'Our net losses were $46.8 million and $27.5 million for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had an accumulated deficit of $228.7 million.'
- Older filing described HMB-002 as 'a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease' changed to 'a monovalent antibody in Phase 1/2 clinical development for subcutaneous prophylactic treatment of Von Willebrand Disease'.
- Older filing described preclinical programs as 'several preclinical programs focusing on coagulation disorders' changed to 'several preclinical programs focusing on coagulation disorders such as HMB-003'.
- Older filing's first bullet referred to 'our ongoing Phase 1/2 clinical trial of sutacimig...our ongoing Phase 2 clinical trial of sutacimig...our ongoing Phase 1/2 clinical trial of HMB-002' changed to 'our ongoing clinical development of sutacimig...our ongoing clinical development of HMB-002'.
- Older filing's milestone/royalty bullet did not include Gubra; newer filing adds Gubra Agreement.
- Notes:
- The newer filing text appears truncated mid-sentence after 'there are any third-party challenges', so a full comparison of the 'In addition, our expenses will further increase' section may be incomplete.
- A new bullet about third-party challenges to intellectual property appearing in the newer filing cannot be fully attributed as an addition because the newer filing is cut off and the older filing appears to contain a matching bullet item.
Risk Factors
- Added:
- Newer filing adds 'along with several preclinical programs focusing on coagulation disorders, such as HMB-003' to the description of financial resources and efforts devoted to research and development.
- Newer filing reports net losses of $46.8 million for the six months ended June 30, 2026.
- Newer filing reports accumulated deficit of $228.7 million as of June 30, 2026.
- Newer filing adds 'including HMB-003 in patients with heavy menstrual bleeding' to the bullet about advancing clinical development of product candidates.
- Newer filing adds 'including HMB-003' to the bullet about advancing research and preclinical activities and discovering and developing additional product candidates.
- Newer filing adds 'and to Gubra A/S, or Gubra, under our collaboration agreement with Gubra,' to the bullet about milestone, royalty, or other payments.
- Removed:
- Older filing reports net losses of $22.7 million for the three months ended March 31, 2026.
- Older filing reports accumulated deficit of $204.5 million as of March 31, 2026.
- Reworded:
- The introductory phrase in the bullet list changed from 'We anticipate that our expenses will increase substantially, if and as, we:' (older) to 'We anticipate that our expenses will increase substantially if and as we:' (newer).
- Notes:
- The newer filing text is truncated mid-sentence at the end of the provided excerpt ('may never generate revenues tha'), so no comparison was possible beyond that point.
- The older filing text appears to be truncated mid-sentence as well ('we are unable to accurately predict the timing or amount'), limiting comparison of that paragraph.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-1616 buys ($55M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-06-16. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about COAG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding COAG as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 5,028,570
- Reported value $184,699,377
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about COAG's institutional holders → See what each manager we track holds →
Short interest (FINRA)
COAG had 3,390,130 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
COAG had 7.26% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.18 days to cover at the same settlement.
- Reported short interest (shares) 3,390,130
- Short interest (% of shares outstanding) 7.26%
- Prior settlement (shares) 2,641,038
- Reported change 28.36%
- Days to cover (reported) 4.18
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Hemab Therapeutics Holdings, Inc. is found in…
Frequently asked questions
What does Hemab Therapeutics Holdings, Inc. (COAG) do?
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. The company's pipeline consists of bispecific and monovalent antibodies targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease, as well as preclinical programs for heavy menstrual bleeding.
What sector is Hemab Therapeutics Holdings, Inc. (COAG) in?
Hemab Therapeutics Holdings, Inc. (COAG) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is Hemab Therapeutics Holdings, Inc. (COAG) overbought or oversold right now?
Hemab Therapeutics Holdings, Inc. (COAG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on COAG come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.